يعرض 1 - 20 نتائج من 20 نتيجة بحث عن '"Volodina, M."', وقت الاستعلام: 0.48s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المساهمون: GeneTechnology, ООО «ГеноТехнология»

    المصدر: Advances in Molecular Oncology; Том 5, № 2 (2018); 62-70 ; Успехи молекулярной онкологии; Том 5, № 2 (2018); 62-70 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2018-5-2

    وصف الملف: application/pdf

    Relation: https://umo.abvpress.ru/jour/article/view/149/143; Scanlan M. J., Simpson A. J., Old L. J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1. PMID: 14738373.; Chen Y. T., Scanlan M. J., Sahin U. et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94(5):1914–8. PMID: 9050879.; Scanlan M. J., Gure A. O., Jungbluth A. A. et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22–32. PMID: 12445278.; Simpson A. J., Caballero O. L., Jungbluth A. et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5(8):615–25. DOI:10.1038/nrc1669. PMID: 16034368.; Mirandola L., Cannon M. J., Cobos E. et al. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol 2011;30(2–3):127–37. DOI:10.3109/08830185.2011.572504. PMID: 21557639.; Мисюрин В. А. Х-хромосомные раково-тестикулярные гены. Российский биотерапевтический журнал 2014;13(2):3–9.; Fratta E., Coral S., Covre A. et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 2011;5(2):164–82. DOI:10.1016/j.molonc.2011.02.001. PMID: 21376678.; Song M. H., Ha J. C., Lee S. M. et al. Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun 2011;408(2):195–201. DOI:10.1016/j.bbrc.2011.02.077. PMID: 21338577.; Chen Y. T., Ross D. S., Chiu R. et al. Multiple cancer/testis antigens are preferentially expressed in hormonereceptor negative and high-grade brease cancers. PLoS One 2011;6(3):17876. DOI:10.1371/journal.pone.0017876. PMID: 21437249.; Boss D. S., Glen H., Beijnen J. H. et al. Serum β-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori 2011;97(12):109–14. PMID: 21528673.; Silina K., Zayakin P., Kalnina Z. et al. Sperm-associated antigens as targets for cancer immunotheraphy: expression pattern and humoral immune response in cancer patients. J Immunother 2011;34(1):28–44. DOI:10.1097/CJI.0b013e3181fb64fa. PMID: 21150711.; Maruyama M., Yoshitake Н.Т.Н., Takamori K., Araki Y. Molecular expression of Ly6k, a putative glycosylphosphatidyl- inositol-anchored membrane protein on the mouse testicular germ cells. Biochem Biophys Res Commun 2010;402(1):75–81. DOI:10.1016/j.bbrc.2010.09.117. PMID: 20920470.; Matsuda R., Enokida H., Chiyomaru T. et al. LY6K is a novel molecular target in blader cancer on basis of integrate genome-wide profiling. Br J Cancer 2011;104(2):376–86. DOI:10.1038/sj.bjc.6605990. PMID: 21063397.; Li F. Q., Liu Q., Han Y. L. et al. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer 2010;10:429. DOI:10.1186/1471-2407-10-429. PMID: 20712874.; Demento S. L., Siefert A. L., Bandyopadhyay A. et al. Pathogenassociated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 2011;29(6):294–306. DOI:10.1016/j.tibtech.2011.02.004. PMID: 21459467.; Forghanifard M. M., Gholamin M., Farshchian M. et al. Cancer-testisgene expression profiling in esophageal squamous cell carcinoma: identificationof specific tumor marker and potential targets for immunotherapy. Cancer Biol Ther 2011;12(3):191–7. PMID: 21613820.; Gaugler B., van den Eynde B., van der Bruggen P. et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179(3):921–30. PMID: 8113684.; Ng А.К. Diffuse large B-cell lymphoma. Semin Radiat Oncol 2007;17(3):169–75. DOI:10.1016/j.semradonc.2007.02.002. PMID: 17591563.; Weigert O., Unterhalt M., Hiddemann W., Dreyling M. Current man-agement of mantle cell lymphoma. Drugs 2007;67(12):1689–702. PMID: 17683170.; Richardson P. G., Mitsiades C., Schlossman R. et al. New drugs for myeloma. Oncologist 2007;12(6):664–89. DOI:10.1634/theoncologist.12-6-664. PMID: 17602058.; Harris N. L., Jaffe E. S., Diebold J. et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10(12):1419–32. PMID: 10643532.; Veelken H., Osterroth F. Vaccination strategies in the treatment of lymphomas. Oncology 2002;62(3):187–200. DOI:10.1159/000059565. PMID: 12065865.; Bogen B., Ruffini P. A., Corthay A. et al. Idiotype-specific immu-notherapy in multiple myeloma: suggestions for future directions of research. Haematologica 2006;91(7):941–8. PMID: 16818282.; Richardson P. G., Sonneveld P., Schuster M. et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-toevent results of the APEX trial. Blood 2007;110(10): 3557–60. DOI:10.1182/blood-2006-08-036947. PMID: 17690257.; Engelhardt M., Udi J., Kleber M. et al. European myeloma network: the 3rd Trialist forum consensus statement from the European experts meeting on multiple myeloma. Leuk Lymphoma 2010;51(11):2006–11. DOI:10.3109/10428194.2010.516378. PMID: 20807087.; Kono K., Mizukami Y., Daigo Y. et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009;100(8):1502–9.; Barlogie B., Shaughnessy J., Tricot G. et al. Treatment of multiple myeloma. Blood 2004;103(1):20–32. DOI:10.1182/blood-2003-04-1045. PMID: 12969978.; Bakkus M. H., Bouko Y., Samson D. et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASOPCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004; 126(5):665–74. DOI:10.1111/j.1365-2141.2004.05120.x. PMID: 15327517.; van Rhee F., Szmania S. M., Zhan F. et al. NY-ESO-1 is highly expressed in poorprognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005;105(10):3939–44. DOI:10.1182/blood-2004-09-3707. PMID: 15671442.; van Duin M., Broy A., de Knegt Y. et al. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica 2011;96(11):1662–9. DOI:10.3324/haematol.2010.037978. PMID: 21791470.; https://umo.abvpress.ru/jour/article/view/149

  3. 3
  4. 4
  5. 5
    Academic Journal
  6. 6
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
    Academic Journal
  20. 20